United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - aztreonam (unii: g2b4ve5gh8) (aztreonam - unii:g2b4ve5gh8) - aztreonam 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, usp and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis, pseudomonas aeruginosa, enterobacter cloacae, klebsiella oxytoca *, citrobacter species*, and serratia marcescens *. lower respiratory t

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - aztreonam (unii: g2b4ve5gh8) (aztreonam - unii:g2b4ve5gh8) - aztreonam 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, usp and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis, pseudomonas aeruginosa, enterobacter cloacae, klebsiella oxytoca *, citrobacter species*, and serratia marcescens *. lower respiratory

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - aztreonam (unii: g2b4ve5gh8) (aztreonam - unii:g2b4ve5gh8) - aztreonam 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, usp and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis, pseudomonas aeruginosa, enterobacter cloacae, klebsiella oxytoca *, citrobacter species*, and serratia marcescens *. lower respiratory t

United States - English - NLM (National Library of Medicine)

hospira, inc. - aztreonam (unii: g2b4ve5gh8) (aztreonam - unii:g2b4ve5gh8) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, usp and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli , klebsiella pneumoniae , proteus mirabilis , pseudomonas aeruginosa , enterobacter cloacae , klebsiella oxytoca 1, citrobacter species1, and serratia marcescens 1. lower respiratory tract infections , including pneumonia and bronchitis caused by escherichia coli , klebsiella pneumoniae , pseudomonas aeruginosa , haemophilus influenzae , proteus mirabilis , enterobacter species, and serratia marcescens 1. septicemia caused by escherichia coli , klebsiella pneumoniae , pseudomonas aeruginosa , proteus mirabilis 1, serratia marcescens 1, and enterobacter species. skin and skin-structure infections , including those associated with postoperative wounds, ulcers, and burns, caused by escherichia coli , proteus mirabilis , serratia marcescens , enterobacter species, pseudomonas aeruginosa , klebsiella pneumoniae , and citrobacter species1. intra-abdominal infections , including peritonitis caused by escherichia coli , klebsiella species including k. pneumoniae , enterobacter species including e. cloacae 1, pseudomonas aeruginosa , citrobacter species1 including c. freundii 1, and serratia species1 including s. marcescens 1. gynecologic infections , including endometritis and pelvic cellulitis caused by escherichia coli , klebsiella pneumoniae 1, enterobacter species1 including e. cloacae 1, and proteus mirabilis 1. aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. aztreonam for injection is effective against most of the commonly encountered gram-negative aerobic pathogens seen in general surgery. concurrent initial therapy with other antimicrobial agents and aztreonam for injection is recommended before the causative organism(s) is known in seriously ill patients who are also at risk of having an infection due to gram-positive aerobic pathogens. if anaerobic organisms are also suspected as etiologic agents, therapy should be initiated using an anti-anaerobic agent concurrently with aztreonam for injection (see dosage and administration ). certain antibiotics (eg, cefoxitin, imipenem) may induce high levels of beta-lactamase in vitro in some gram-negative aerobes such as enterobacter and pseudomonas species, resulting in antagonism to many beta-lactam antibiotics including aztreonam. these in vitro findings suggest that such beta-lactamase inducing antibiotics not be used concurrently with aztreonam. following identification and susceptibility testing of the causative organism(s), appropriate antibiotic therapy should be continued. this preparation is contraindicated in patients with known hypersensitivity to aztreonam or any other component in the formulation.

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - aztreonam (unii: g2b4ve5gh8) (aztreonam - unii:g2b4ve5gh8) - aztreonam 1 g in 50 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of azactam (aztreonam injection) and other antibacterial drugs, azactam should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. azactam is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli , klebsiella pneumoniae , proteus mirabilis , pseudomonas aeruginosa , enterobacter cloacae , klebsiella oxytoca *, citrobacter species*, and serratia marcescens *. lower respiratory tract infections , including

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - aztreonam (unii: g2b4ve5gh8) (aztreonam - unii:g2b4ve5gh8) - aztreonam 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of azactam (aztreonam for injection, usp) and other antibacterial drugs, azactam should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. azactam is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by escherichia coli , klebsiella pneumoniae , proteus mirabilis , pseudomonas aeruginosa , enterobacter cloacae , klebsiella oxytoca *, citrobacter species*, and serratia marcescens *. lower respiratory tract infections ,

United States - English - NLM (National Library of Medicine)

gilead sciences, inc. - aztreonam (unii: g2b4ve5gh8) (aztreonam - unii:g2b4ve5gh8) - aztreonam 75 mg in 1 ml - cayston® is indicated to improve respiratory symptoms in cystic fibrosis (cf) patients with pseudomonas aeruginosa . safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with fev1 <25% or >75% predicted, or patients colonized with burkholderia cepacia [see clinical studies (14)]. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cayston and other antibacterial drugs, cayston should be used only to treat patients with cf known to have pseudomonas aeruginosa in the lungs. cayston is contraindicated in patients with a known allergy to aztreonam. risk summary available data on cayston use in pregnant women is insufficient to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; however, systemic absorption of aztreonam following inhaled administration is expected to be minimal [see clinical pharmacology (12.3)]. there are risks to the mother associated with cystic fi

United States - English - NLM (National Library of Medicine)

cardinal health - aztreonam (unii: g2b4ve5gh8) (aztreonam - unii:g2b4ve5gh8) - aztreonam 1 g

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - aztreonam -

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

hainan hualon pharmaceutical co. ltd., china - aztreonam - powder for solution for injection - 0.5 g